Dublin, Ireland, April 6th, 2011 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has strengthened the leadership of its Medical Imaging division through the promotion of Kornelia Martin, Ph.D. as Vice President, European Operations. In her new role, Dr. Martin will be responsible for driving ICON Medical Imaging’s activities in Europe, which were expanded through the acquisition of Timaq Medical Imaging in May 2010.
“Supporting our European clients who are increasingly using imaging technology in their development programs continues to be a focus for us,” commented Ted Gastineau, President, ICON Medical Imaging. “Our acquisition of Timaq has greatly boosted our capabilities in Europe and Kornelia’s scientific and operational expertise will further strengthen our presence in the region.”
Dr. Martin joined ICON Medical Imaging in January 2009 as Senior Director, Business Development. Prior to joining ICON, Dr. Martin held sales and scientific roles in Europe and the US for FOCUS Clinical Drug Development, Synarc and Baxter Oncology, Cellular Therapy. An x-ray technician by training, Dr. Martin was awarded her Ph.D. in Human Biology from Philipps University Marburg, Germany, through her work in establishing new prognostic and predictive factors for breast cancer patients.
About ICON Medical Imaging
ICON Medical Imaging provides medical imaging based product development services to the pharmaceutical, biotechnology and medical device industries and has assisted over 100 companies in hundreds of clinical trials resulting in more than 20 NDA/BLA submissions for regulatory approval.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has around 7,800 employees, operating from 77 locations in 39 countries.
Further information is available at www.iconplc.com